BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/21/2020 1:38:19 AM | Browse: 605 | Download: 1173
 |
Received |
|
2020-02-17 07:22 |
|
Peer-Review Started |
|
2020-02-17 14:14 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-03-28 13:41 |
|
Revised |
|
2020-04-09 04:41 |
|
Second Decision |
|
2020-07-21 09:03 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2020-07-26 21:14 |
|
Articles in Press |
|
2020-07-26 21:14 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2020-08-13 07:03 |
|
Publish the Manuscript Online |
|
2020-08-21 01:38 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Effectiveness of a novel, fixed dose combination of netupitant and palonosetron in prevention of chemotherapy induced nausea and vomiting: A real-life study from India
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Bharat Vaswani, Sagar Bhagat, Saiprasad Patil and Hanmant Barkate |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Sagar Bhagat, MD, Doctor, Medical Services, Glenmark Pharmaceuticals limited, B D Sawant road, Andheri East, Mumbai, Maharashtra 400099, India. sagar.bhagat@glenmarkpharma.com |
| Key Words |
Chemotherapy induced nausea vomiting; Netupitant; Palonosetron; Cancer; Chemotherapy; |
| Core Tip |
A fixed-dose combination of Netupitant (300 mg) and Palonosetron (0.50 mg) indicated for the prevention of acute and delayed phase of nausea-vomiting in patients on highly and moderately emetogenic chemotherapeutic regimen was recently approved in India. There was no data on the effectiveness of this fixed dose combination in Indian patients in real world setting,the pervious data available was part of regulatory trial conducted in controlled environment, which may not give the real picture of the usage of the molecule in clinical setting. So to look for the effectiveness of the molecule in real world setting this study was conducted among. |
| Publish Date |
2020-08-21 01:38 |
| Citation |
Vaswani B, Bhagat S, Patil S, Barkate H. Effectiveness of a novel, fixed dose combination of netupitant and palonosetron in prevention of chemotherapy induced nausea and vomiting: A real-life study from India. World J Clin Oncol 2020; 11(8): 606-613 |
| URL |
https://www.wjgnet.com/2218-4333/full/v11/i8/606.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v11.i8.606 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
